Poseida Therapeutics (PSTX)
(Delayed Data from NSDQ)
$2.07 USD
-0.09 (-4.17%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.06 -0.01 (-0.48%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Poseida Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 65 | 130 | 31 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 65 | 130 | 31 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 194 | 190 | 173 | 127 | 86 |
Income After Depreciation & Amortization | -130 | -60 | -141 | -127 | -86 |
Non-Operating Income | 15 | 3 | 20 | 0 | 3 |
Interest Expense | 9 | 6 | 3 | 4 | 4 |
Pretax Income | -123 | -63 | -125 | -130 | -87 |
Income Taxes | 0 | 1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -123 | -64 | -125 | -130 | -87 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -123 | -64 | -125 | -130 | -87 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -131 | -56 | -136 | -123 | -83 |
Depreciation & Amortization (Cash Flow) | -2 | 4 | 5 | 3 | 2 |
Income After Depreciation & Amortization | -130 | -60 | -141 | -127 | -86 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 90.19 | 71.95 | 62.24 | 36.00 | 12.62 |
Diluted EPS Before Non-Recurring Items | -1.37 | -0.89 | -2.01 | -3.61 | -6.86 |
Diluted Net EPS (GAAP) | -1.37 | -0.89 | -2.01 | -3.61 | -6.86 |
Fiscal Year end for Poseida Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 25.00 | 9.35 | 20.01 | 10.34 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 25.00 | 9.35 | 20.01 | 10.34 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 50.91 | 45.57 | 47.87 | 49.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -25.91 | -36.22 | -27.86 | -39.52 |
Non-Operating Income | NA | 2.83 | 6.79 | 2.54 | 2.70 |
Interest Expense | NA | 2.27 | 2.24 | 2.14 | 2.03 |
Pretax Income | NA | -25.35 | -31.67 | -27.46 | -38.85 |
Income Taxes | NA | 0.00 | 0.11 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -25.35 | -31.78 | -27.46 | -38.85 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -25.35 | -31.78 | -27.46 | -38.85 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 95.62 | 91.90 | 86.80 | 86.27 |
Diluted EPS Before Non-Recurring Items | NA | -0.27 | -0.35 | -0.32 | -0.45 |
Diluted Net EPS (GAAP) | NA | -0.25 | -0.35 | -0.32 | -0.45 |